Long-term Outcome of Percutaneous Coronary Intervention: the Significance of Native Coronary Artery Disease Progression

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2011 Sep 21

PMID 21932326

Citations 6

Authors

Athanasios Moulias

Dimitrios Alexopoulos

Affiliations

Soon will be listed here.

Abstract

The extensive use of stents during percutaneous coronary intervention (PCI) is associated with concerns about their potential adverse effects. In-stent restenosis and stent thrombosis definitely significantly affect the PCI outcome. However, review of recent relevant studies suggests that stent-related problems may have been somewhat overestimated when compared to coronary artery disease (CAD) progression at nonstented coronary segments as causative factors of adverse cardiac clinical events late (>30 days) post-PCI. Both stent-related problems and native CAD progression have to be equally addressed to optimize the PCI clinical benefit.

Citing Articles

Predictors of Stent Restenosis in Han and Uygur Patients with Coronary Heart Disease after PCI in the Xinjiang Region.

Wang J, Yang Y, Zhang L, He P, Mu H Cardiol Res Pract. 2022; 2022:7845108.

PMID: 35958295 PMC: 9357810. DOI: 10.1155/2022/7845108.

A SNP involved in alternative splicing of is associated with clopidogrel resistance in coronary heart disease in Chinese population.

Zhang S, Wang J, Zhang A, Zhang X, You T, Xie D Aging (Albany NY). 2020; 12(24):25684-25699.

PMID: 33232268 PMC: 7803500. DOI: 10.18632/aging.104177.

The effect of the debulking by excimer laser coronary angioplasty on long-term outcome compared with drug-coating balloon: insights from optical frequency domain imaging analysis.

Sato T, Tsuchida K, Yuasa S, Taya Y, Koshikawa T, Tanaka K Lasers Med Sci. 2019; 35(2):403-412.

PMID: 31264007 DOI: 10.1007/s10103-019-02833-1.

Intra-Arterial Drug and Light Delivery for Photodynamic Therapy Using Visudyne®: Implication for Atherosclerotic Plaque Treatment.

Jain M, Zellweger M, Frobert A, Valentin J, van den Bergh H, Wagnieres G Front Physiol. 2016; 7:400.

PMID: 27672369 PMC: 5018500. DOI: 10.3389/fphys.2016.00400.

Treatment of in-stent restenosis with excimer laser coronary angioplasty: benefits over scoring balloon angioplasty alone.

Hirose S, Ashikaga T, Hatano Y, Yoshikawa S, Sasaoka T, Maejima Y Lasers Med Sci. 2016; 31(8):1691-1696.

PMID: 27516177 DOI: 10.1007/s10103-016-2039-z.

References

Mauri L, Hsieh W, Massaro J, Ho K, DAgostino R, Cutlip D . Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356(10):1020-9. DOI: 10.1056/NEJMoa067731. View

Alexopoulos D, Xanthopoulou I, Davlouros P, Damelou A, Mazarakis A, Chiladakis J . Mechanisms of nonfatal acute myocardial infarction late after stent implantation: the relative impact of disease progression, stent restenosis, and stent thrombosis. Am Heart J. 2010; 159(3):439-45. DOI: 10.1016/j.ahj.2009.12.011. View

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U . EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009; 16(2):121-37. DOI: 10.1097/HJR.0b013e3283294b1d. View

Cutlip D, Windecker S, Mehran R, Boam A, Cohen D, van Es G . Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344-51. DOI: 10.1161/CIRCULATIONAHA.106.685313. View

Johnson C, Waters D, DeMicco D, Breazna A, Bittner V, Greten H . Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT].... Am J Cardiol. 2008; 102(10):1312-7. DOI: 10.1016/j.amjcard.2008.07.023. View

Virmani R, Kolodgie F, Burke A, Farb A, Schwartz S . Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20(5):1262-75. DOI: 10.1161/01.atv.20.5.1262. View

Serruys P, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G . A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331(8):489-95. DOI: 10.1056/NEJM199408253310801. View

Kimura T, Abe K, Shizuta S, Odashiro K, Yoshida Y, Sakai K . Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002; 105(25):2986-91. DOI: 10.1161/01.cir.0000019743.11941.3b. View

Leon M, Allocco D, Dawkins K, Baim D . Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. JACC Cardiovasc Interv. 2009; 2(6):504-12. DOI: 10.1016/j.jcin.2009.04.004. View

10.

Farb A, Sangiorgi G, Carter A, Walley V, Edwards W, Schwartz R . Pathology of acute and chronic coronary stenting in humans. Circulation. 1999; 99(1):44-52. DOI: 10.1161/01.cir.99.1.44. View

11.

Delhaye C, Sudre A, Lemesle G, Marechaux S, Broucqsault D, Hennache B . Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. Cardiovasc Revasc Med. 2009; 10(3):144-50. DOI: 10.1016/j.carrev.2009.01.005. View

12.

Chhatriwalla A, Nicholls S, Wang T, Wolski K, Sipahi I, Crowe T . Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol. 2009; 53(13):1110-5. DOI: 10.1016/j.jacc.2008.09.065. View

13.

Hong M, Park D, Lee C, Lee S, Kim Y, Kang D . Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv. 2009; 2(7):679-88. DOI: 10.1016/j.jcin.2009.03.015. View

14.

Schoenenberger A, Jamshidi P, Kobza R, Zuber M, Stuck A, Pfisterer M . Progression of coronary artery disease during long-term follow-up of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II). Clin Cardiol. 2010; 33(5):289-95. PMC: 6653251. DOI: 10.1002/clc.20775. View

15.

Harrington R, Hasselblad V, Califf R . Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?. J Am Coll Cardiol. 2008; 51(1):33-6. DOI: 10.1016/j.jacc.2007.08.051. View

16.

Bayturan O, Kapadia S, Nicholls S, Tuzcu E, Shao M, Uno K . Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010; 55(24):2736-42. DOI: 10.1016/j.jacc.2010.01.050. View

17.

Glaser R, Selzer F, Faxon D, Laskey W, Cohen H, Slater J . Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2004; 111(2):143-9. DOI: 10.1161/01.CIR.0000150335.01285.12. View

18.

Smith Jr S, Allen J, Blair S, Bonow R, Brass L, Fonarow G . AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006; 47(10):2130-9. DOI: 10.1016/j.jacc.2006.04.026. View

19.

Cohen D, Houser F, Mack M, Simon A, Battaglia S, Tarkington L . Practice and outcomes of percutaneous coronary intervention in the community before drug-eluting stents: a report from the HCA database. J Invasive Cardiol. 2003; 15(3):121-7. View

20.

Razzouk L, Muntner P, Bansilal S, Kini A, Aneja A, Mozes J . C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J. 2009; 158(2):277-83. DOI: 10.1016/j.ahj.2009.05.026. View